Karmali Kunal N, Ning Hongyan, Goff David C, Lloyd-Jones Donald M
Department of Preventive Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL (K.N.K., H.N., D.M.L.J.).
Colorado School of Public Health, University of Colorado Anschutz Medical Center, Aurora, CO (D.C.G.).
J Am Heart Assoc. 2015 Sep 21;4(9):e002126. doi: 10.1161/JAHA.115.002126.
We determined the proportion of atherosclerotic cardiovascular disease (ASCVD) events that occur across the spectrum of systolic blood pressure (SBP) and assessed whether multivariable risk assessment can identify persons who experience ASCVD events at all levels of SBP, including those with goal levels.
Participants aged 45 to 64 years from the Framingham Offspring and Atherosclerosis Risk in Communities studies were stratified based on treated and untreated SBP levels (<120, 120 to 129, 130 to 139, 140 to 149, 150 to 159, ≥160 mm Hg). We determined the number of excess ASCVD events in each SBP stratum by calculating the difference between observed and expected events (ASCVD event rate in untreated SBP <120 mm Hg was used as the reference). We categorized participants into 10-year ASCVD risk groups using the Pooled Cohort risk equations. There were 18 898 participants (78% white; 22% black) who were followed for 10 years. We estimated 427 excess ASCVD events, of which 56% (109 of 197) and 50% (115 of 230), respectively, occurred among untreated and treated participants with elevated SBP who were not recommended for antihypertensive therapy. Among untreated participants, 10-year ASCVD risk ≥7.5% identified 64% of those who experienced an ASCVD at 10 years and 30% of those who did not. Multivariable risk assessment was less useful in baseline-treated participants.
Half of excess ASCVD events occurred in persons with elevated SBP who were not currently recommended for antihypertensive therapy. Multivariable risk assessment may help identify those likely to benefit from further risk-reducing therapies. These findings support consideration of multivariable risk in guiding prevention across the spectrum of SBP.
我们确定了在收缩压(SBP)范围内发生的动脉粥样硬化性心血管疾病(ASCVD)事件的比例,并评估了多变量风险评估能否识别出在所有SBP水平(包括目标水平)发生ASCVD事件的人群。
来自弗雷明汉后代研究和社区动脉粥样硬化风险研究的45至64岁参与者,根据治疗和未治疗的SBP水平(<120、120至129、130至139、140至149、150至159、≥160mmHg)进行分层。我们通过计算观察到的事件与预期事件之间的差异,确定每个SBP分层中ASCVD事件的超额数量(未治疗SBP<120mmHg时的ASCVD事件发生率用作参考)。我们使用合并队列风险方程将参与者分为10年ASCVD风险组。共有18898名参与者(78%为白人;22%为黑人),随访10年。我们估计有427例ASCVD超额事件,其中分别有56%(197例中的109例)和50%(230例中的115例)发生在未接受降压治疗且SBP升高的未治疗和已治疗参与者中。在未治疗的参与者中,10年ASCVD风险≥7.5%可识别出10年时发生ASCVD的参与者中的64%以及未发生ASCVD的参与者中的30%。多变量风险评估在基线已治疗的参与者中作用较小。
一半的ASCVD超额事件发生在目前不建议进行降压治疗但SBP升高的人群中。多变量风险评估可能有助于识别那些可能从进一步降低风险治疗中获益的人群。这些发现支持在指导全范围SBP预防中考虑多变量风险。